News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Exec Charged With Insider Trading


8/3/2012 7:01:11 AM

U.S. regulators were so suspicious of the circumstances surrounding Gilead Sciences Inc. (GILD) (GILD)’s Nov. 21 announcement it was buying Pharmasset Inc. for $11 billion that they opened an insider-trading investigation that day. “The volume was huge and the deal premium was huge, so we looked at the underlying trading,” U.S. Securities and Exchange Commission attorney Mary P. Hansen said in a phone interview. “We were looking at anyone who bought shares.” The probe, which the Justice Department joined, resulted yesterday in the arrest of Robert Ramnarine, a Bristol-Myers Squibb Co. (BMY) (BMY) executive.

Read at BusinessWeek
Read at New York Times
Read at The Day
Read at Wall Street Journal

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES